{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:30:42Z","timestamp":1795059042456,"version":"4.10.2"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128251","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:20:07Z","timestamp":1768929607000},"page":"128251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya"],"prefix":"10.1016","volume":"75","author":[{"given":"Kerstin","family":"Kling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Falman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Branke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sch\u00f6nfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gr\u00fcnewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2026.128251_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010069","article-title":"The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines","volume":"16","author":"Bettis","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128251_bb0010","series-title":"Chikungunya fever. Nature Reviews Disease Primers","volume":"9(1)","author":"Bartholomeeusen","year":"2023"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128251_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008159","article-title":"A comparative analysis of the 2007 and 2017 Italian chikungunya outbreaks and implication for public health response","volume":"14","author":"Caputo","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128251_bb0020","author":"WHO"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128251_bb0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antivir Res"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128251_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000914","article-title":"The global burden of chikungunya fever among children: a systematic literature review and meta-analysis","volume":"2","author":"Nyamwaya","year":"2022","journal-title":"PLOS Global Public Health"},{"key":"10.1016\/j.vaccine.2026.128251_bb0035","series-title":"Chikungunya Outbreak Spreads from Indian Ocean Islands, Posing Global Risk","author":"Watch HP","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128251_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.01297","article-title":"Chikungunya virus: an emergent arbovirus to the south American continent and a continuous threat to the world","volume":"11","author":"Cunha","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2026.128251_bb0045","year":"2025","journal-title":"Invasive mosquitoes"},{"key":"10.1016\/j.vaccine.2026.128251_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2021.102168","article-title":"Chikungunya and arthritis: an overview","volume":"44","author":"Kumar","year":"2021","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128251_bb0055","series-title":"Tropism of the Chikungunya Virus Viruses","first-page":"2","volume":"11","author":"Matusali","year":"2019"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128251_bb0060","article-title":"Chikungunya fever and rheumatoid arthritis: a systematic review and Meta-analysis. Trop med","volume":"10","author":"Amaral","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128251_bb0065","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.chom.2024.02.011","article-title":"Pathophysiology of chikungunya virus infection associated with fatal outcomes","volume":"32","author":"de Souza","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128251_bb0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1473-3099(23)00810-1","article-title":"Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study","volume":"24","author":"Kang","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128251_bb0075","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/tmi.13711","article-title":"Epidemiological burden of chikungunya fever in Brazil, 2016 and 2017","volume":"27","author":"Vidal","year":"2022","journal-title":"Trop Med Int Health"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128251_bb0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.4269\/ajtmh.2007.77.727","article-title":"A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006","volume":"77","author":"Renault","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128251_bb0085","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7223a5","article-title":"Notes from the field: chikungunya outbreak \u2014 Paraguay, 2022\u20132023","volume":"72","author":"Torales","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128251_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004630","article-title":"Chikungunya fever cases identified in the veterans health administration system, 2014","volume":"10","author":"Perti","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128251_bb0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/tmi.14088","article-title":"Risk factors for mortality in patients with chikungunya: a systematic review and meta-analysis","volume":"30","author":"Micheleto","year":"2025","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2026.128251_bb0100","article-title":"Clinical profile and factors associated with hospitalization during a chikungunya epidemic in Ceara","volume":"52","author":"Pinto","year":"2019","journal-title":"Brazil Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2026.128251_bb0105","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40259-024-00677-y","article-title":"Chikungunya virus vaccines: a review of IXCHIQ and PXVX0317 from pre-clinical evaluation to licensure","volume":"38","author":"Weber","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2026.128251_bb0115","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.vaccine.2026.128251_bb0120","series-title":"ANNEX I Summary of Product Characteristics - Vimkunya","author":"Bavarian Nordic","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128251_bb0125","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128251_bb0130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"10394","key":"10.1016\/j.vaccine.2026.128251_bb0135","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"issue":"10487","key":"10.1016\/j.vaccine.2026.128251_bb0140","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(25)00345-9","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Richardson","year":"2025","journal-title":"Lancet"},{"issue":"10487","key":"10.1016\/j.vaccine.2026.128251_bb0145","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(25)00372-1","article-title":"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial","volume":"405","author":"Tindale","year":"2025","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128251_bb0150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(24)00357-8","article-title":"Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study","volume":"24","author":"McMahon","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128251_bb0155","first-page":"04","article-title":"Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents","volume":"04","author":"Buerger","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128251_bb0160","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128251_bb0165","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128251_bb0170","article-title":"Comprehensive assessment of reactogenicity and safety of the live-attenuated chikungunya vaccine (IXCHIQ((R)))","volume":"13","author":"Maurer","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128251_bb0175","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128251_bb0180","series-title":"Assessment report. Procedure under Article 20 of Regulation (EC) No 726\/2004 resulting from pharmacovigilance data","author":"European Medicines Agency (EMA)","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128251_bb0185","article-title":"Fatal adverse event after VLA1553 chikungunya vaccination in an elderly patient: a case report from Reunion Island. Open forum","volume":"12(9):ofaf550","author":"Mosnier","year":"2025","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.128251_bb0190","series-title":"FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live)","author":"Food and Drug Administration (FDA)","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128251_bb0195","series-title":"FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated","author":"Food and Drug Administration (FDA)","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128251_bb0200","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.vaccine.2026.128251_bb0205","unstructured":"European Medicines Agency (EMA). Ixchiq (Chikungunya vaccine (live)): new contraindication in patients aged 65 years and older while EU-wide review is ongoing 2025 Available from: https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-ixchiq-chikungunya-vaccine-live-new-contraindication-patients-aged-65-years-older-while-eu-wide-review-ongoing_en.pdf; 2025."},{"key":"10.1016\/j.vaccine.2026.128251_bb0210","author":"EMA"},{"key":"10.1016\/j.vaccine.2026.128251_bb0215","author":"Paul Ehrlich Institut"},{"issue":"44","key":"10.1016\/j.vaccine.2026.128251_bb0220","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.44.2500792","article-title":"Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to august 2025","volume":"30","author":"Simone","year":"2025","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128251_bb0225","series-title":"Guidance on an adapted evidence to recommendation process for National Immunization Technical Advisory Groups","author":"World Health Organization Regional Office for Europe","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128251_bb0230","first-page":"28","article-title":"Standing vaccination Committee at the Robert Koch Institute. STIKO recommendation on vaccination against chikungunya. Epidemiologisches","year":"2025","journal-title":"Bulletin"},{"key":"10.1016\/j.vaccine.2026.128251_bb0235","series-title":"Seasonal surveillance of chikungunya virus disease in the EU\/EEA, weekly report","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2025"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:50:08Z","timestamp":1772553008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"alternative-id":["S0264410X26000587"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128251","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128251"}}